MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3899/jrheum.2024-0612

Медицинская библиотека · The Journal of rheumatology · 2025

Tocilizumab (TCZ) for Giant Cell Arteritis: Clinical Outcomes Following Relapses and TCZ Discontinuation Due to Adverse Events.

Nagase Fumika N, Fukui Sho, Takizawa Naoho, Yamaguchi Toshihiro, Oda Nobuhiro, Inokuchi Hajime, Ito Takanori, Watanabe Mitsuru, Suda Masei, Haji Yoichiro, Suyama Yasuhiro, Rokutanda Ryo, Minoda Masahiro, Nomura Atsushi, Uechi Eishi, Tamaki Hiromichi

СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

Tocilizumab (TCZ) is effective for giant cell arteritis (GCA). However, little is known regarding treatment modification and clinical outcomes after unfavorable events such as GCA relapses or TCZ discontinuation due to adverse events (AEs).

METHODS

This multicenter retrospective study included patients with GCA who initiated TCZ from 2008 to 2021 at 5 Japanese hospitals. GCA relapses and TCZ-related AEs were monitored for 2 years after TCZ initiation. In patients with GCA relapses, subsequent clinical courses, including relapse symptoms and treatment modification, were followed for 90 days after the relapses. Similarly, patients who discontinued TCZ because of AEs were additionally followed until 1 year after the TCZ discontinuation to evaluate AEs, relapses, and treatment changes.

RESULTS

Of 62 eligible patients, 10 patients (16%) relapsed after initiating TCZ therapy. Most relapses (8 of 10) occurred after extending TCZ intervals or discontinuing TCZ. Combinations of adjusting TCZ intervals, adjusting glucocorticoid (GC) dose, and/or adding or increasing methotrexate (MTX) therapy could manage the relapses without serious complications. In the entire cohort, AEs occurred in 28 patients (45%), and 8 patients (13%) discontinued TCZ because of AEs. After AE-related TCZ discontinuation, 6 patients attempted to taper GCs without other immunosuppressive therapy (IST), and 4 subsequently relapsed. In contrast, 2 patients who used other IST or biologic therapy could decrease GCs without relapses.

CONCLUSION

Although GCA relapses can occur after initiating TCZ therapy, most relapses can be safely managed by adjusting TCZ, GC, and/or MTX doses. Adding IST or biologic treatments may potentially be related to preventing relapses when patients discontinue TCZ because of AEs.

Для цитирования: Nagase Fumika N, Fukui Sho, Takizawa Naoho, Yamaguchi Toshihiro, Oda Nobuhiro, Inokuchi Hajime, Ito Takanori, Watanabe Mitsuru, Suda Masei, Haji Yoichiro, Suyama Yasuhiro, Rokutanda Ryo, Minoda Masahiro, Nomura Atsushi, Uechi Eishi, Tamaki Hiromichi. Tocilizumab (TCZ) for Giant Cell Arteritis: Clinical Outcomes Following Relapses and TCZ Discontinuation Due to Adverse Events.. The Journal of rheumatology. 2025. DOI: 10.3899/jrheum.2024-0612.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.